RxDoctor Payments Data

Amanda Quarles

Family · Jackson, MSNPI 1699084020

Payments from drug & device makers

$8,514in general payments, 2019–2025

Across 453 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$694
  • Amgen$664
  • SK Life Science, Inc.$537
  • AbbVie$422
  • Avanir Pharmaceuticals, Inc.$410
  • Acadia Pharmaceuticals Inc$392
  • plus $5K from 41 others

What the payments were for

  • Consulting fees$1502%
  • Speaking & faculty fees$771%
  • Food & beverage$8,25197%
  • Education$360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,514 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$23,491
Medicare patients
131
Services billed
239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab52$472,078
Nurtec OdtRimegepant Sulfate55$88,504
Teriflunomide11$62,339
UbrelvyUbrogepant31$36,124
Dalfampridine ErDalfampridine44$18,899
Aimovig AutoinjectorErenumab-Aooe17$15,801
Ajovy AutoinjectorFremanezumab-Vfrm12$11,230
Emgality PenGalcanezumab-Gnlm16$10,642
Oxcarbazepine45$4,728
Mycophenolate Mofetil11$1,653
Propranolol Hcl ErPropranolol Hcl36$1,626
Gabapentin96$1,570
Levetiracetam19$1,320
Baclofen78$1,319
Amitriptyline Hcl77$1,194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$209$88,50455 claims
AbbVieUbrelvy$422$36,12431 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$12$1,65311 claims
Upsher-smith Laboratories LLCTopiramate$23$18517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →